Clinical trials: Headache Disorder
Headache, Tension-Type
Paracetamol With Caffeine to Treat Episodic Tension Type Headache
This study will compare a fast-absorbing paracetamol plus caffeine formula with placebo and an over-the-counter dose of paracetamol and ibuprofen to treat episodic tension headache.
- Trial name
- NCT01755702
- Testing
- Experimental paracetamol + caffeine formulation, ibuprofen marketed formulation, Paracetamol marketed formulation
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- GlaxoSmithKline
Migraine
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.
- Trial name
- NCT06848075
- Testing
- Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg
- Where
- 66 sites in United States
- Volunteers
- 431 people
- Sponsor
- TriGemX Bio, Inc.
Migraine
A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine
The main purpose of this study is to determine the efficacy of the study drug Galcanezumab in Japanese participants with episodic migraine.
- Trial name
- NCT02959177
- Testing
- Galcanezumab
- Where
- 47 sites in Japan
- Volunteers
- 459 people
- Sponsor
- Eli Lilly and Company
Migraine Headache
Study in Participants With Acute Migraines Headaches
This is a Phase 2, multicenter, randomized, double-blind, placebo and active comparator-controlled study of LY2590443 in approximately 200 participants with migraines.
- Trial name
- NCT00804973
- Testing
- LY2590443, Sumatriptan
- Where
- 19 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Chronic Migraine or Episodic Migraine
Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention
To evaluate the effect of AMG 301 compared to placebo on the change from the baseline period in monthly migraine days in subjects with migraine.
- Trial name
- NCT03238781
- Testing
- AMG 301
- Where
- 49 sites in United States, Austria and 6 more
- Volunteers
- 343 people
- Sponsor
- Amgen
Chronic Migraine
Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine
Migraine imposes a substantial burden on patients in terms of diminished daily functioning, quality of life, and financial loss.
- Trial name
- Tx360 (NCT01709708)
- Testing
- Marcaine, Saline
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Tian Medical Inc.
Episodic Migraine Headache
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
The purpose of this study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in subjects with high frequency episodic migraine.
- Trial name
- NCT02025556
- Testing
- LBR-101 High Dose, LBR-101 Low Dose
- Where
- 63 sites in United States
- Volunteers
- 297 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine Disorders
Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)
Study to understand the effects of migraine treatments on blood pressure in participants with migraine. The primary hypothesis is that the effect on semi-recumbent mean arterial pressure following the coadministration of…
- Trial name
- NCT00701389
- Testing
- telcagepant potassium, sumatriptan
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Migraine
Non-Invasive Neurostimulation for the Prevention of Chronic Migraine
The purpose of this multi-center, prospective, double-blind, randomized, sham-controlled pilot study is to study feasibility and collect preliminary clinical data related to the safety and clinical benefits of daily use of…
- Trial name
- NCT01667250
- Testing
- GammaCore Active Device
- Where
- 6 sites in United States
- Volunteers
- 59 people
- Sponsor
- ElectroCore INC
Migraine
Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults
The purpose of this is study is to compare the efficacy of BHV-3000 (rimegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
- Trial name
- NCT03732638
- Testing
- Rimegepant
- Where
- 93 sites in United States
- Volunteers
- 1,590 people
- Sponsor
- Pfizer
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and…
- Trial name
- NCT02848326
- Testing
- Atogepant
- Where
- 75 sites in United States
- Volunteers
- 834 people
- Sponsor
- Allergan
Migraine Headache
A Study in Migraine Prevention
The primary objective of this study is to measure the change in frequency of migraine attacks per 28 days in migraine patients being treated orally with LY2300559 for 12 weeks.
- Trial name
- NCT01184508
- Testing
- LY2300559
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 87 people
- Sponsor
- Eli Lilly and Company
Migraine, Migraine With Aura
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
Study STS101-007 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute…
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- SUMMIT (NCT04940390)
- Testing
- Dihydroergotamine
- Where
- 127 sites in United States
- Volunteers
- 1,591 people
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Migraine
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
The primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.
- Trial name
- EMBRACE (NCT04252742)
- Testing
- Erenumab
- Where
- 91 sites in United States, Bulgaria and 7 more
- Volunteers
- 512 people
- Sponsor
- Amgen
Episodic Cluster Headache, Chronic Cluster Headache
A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL…
- Trial name
- NCT02797951
- Testing
- Galcanezumab
- Where
- 40 sites in United States, Belgium and 10 more
- Volunteers
- 165 people
- Sponsor
- Eli Lilly and Company
Medication Overuse Headache
Pilot Study of DFN-11 Injection in Medication Overuse Headache
Efficacy and Safety Pilot Study of DFN-11 Injection in Medication Overuse Headache
- Trial name
- NCT02583425
- Testing
- DFN-11 Injection
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Migraine
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine
To evaluate the efficacy and safety of subcutaneous (SC) administration of TEV-48125 [monthly TEV-48125 225 mg (loading dose only: 675 mg) and TEV-48125 675 mg once over a period of 3 months] compared with placebo for preventive…
- Trial name
- NCT03303079
- Testing
- TEV-48125
- Where
- Japan
- Volunteers
- 571 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Migraine Headache
Treatment of Multiple Attacks of Acute Migraine (0462-025)
A study to evaluate rizatriptan for the treatment of multiple attacks of acute migraine compared to placebo.
- Trial name
- NCT00899379
- Testing
- rizatriptan benzoate
- Volunteers
- 473 people
- Sponsor
- Organon and Co
Migraine
Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds
Study Objectives: 1. The primary objective is to characterize the pharmacokinetics of a single oral administration of 50 mg Cambia in pediatric subjects, ages 12-17 years with a diagnosis of episodic migraine with or without…
- Trial name
- NCT02287376
- Testing
- Diclofenac Potassium for Oral Solution
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Depomed
Migraine
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
- Trial name
- NCT05518123
- Testing
- Rimegepant
- Where
- 111 sites in United States, Australia and 12 more
- Volunteers
- 962 people
- Sponsor
- Pfizer